Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 12.563
Filter
4.
Hepatology ; 79(4): 745-746, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38809342
5.
Gastroenterology ; 166(6): 1020-1055, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38763697

ABSTRACT

BACKGROUND & AIMS: Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Endoscopic eradication therapy (EET) can be effective in eradicating BE and related neoplasia and has greater risk of harms and resource use than surveillance endoscopy. This clinical practice guideline aims to inform clinicians and patients by providing evidence-based practice recommendations for the use of EET in BE and related neoplasia. METHODS: The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence and make recommendations. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients, conducted an evidence review, and used the Evidence-to-Decision Framework to develop recommendations regarding the use of EET in patients with BE under the following scenarios: presence of (1) high-grade dysplasia, (2) low-grade dysplasia, (3) no dysplasia, and (4) choice of stepwise endoscopic mucosal resection (EMR) or focal EMR plus ablation, and (5) endoscopic submucosal dissection vs EMR. Clinical recommendations were based on the balance between desirable and undesirable effects, patient values, costs, and health equity considerations. RESULTS: The panel agreed on 5 recommendations for the use of EET in BE and related neoplasia. Based on the available evidence, the panel made a strong recommendation in favor of EET in patients with BE high-grade dysplasia and conditional recommendation against EET in BE without dysplasia. The panel made a conditional recommendation in favor of EET in BE low-grade dysplasia; patients with BE low-grade dysplasia who place a higher value on the potential harms and lower value on the benefits (which are uncertain) regarding reduction of esophageal cancer mortality could reasonably select surveillance endoscopy. In patients with visible lesions, a conditional recommendation was made in favor of focal EMR plus ablation over stepwise EMR. In patients with visible neoplastic lesions undergoing resection, the use of either endoscopic mucosal resection or endoscopic submucosal dissection was suggested based on lesion characteristics. CONCLUSIONS: This document provides a comprehensive outline of the indications for EET in the management of BE and related neoplasia. Guidance is also provided regarding the considerations surrounding implementation of EET. Providers should engage in shared decision making based on patient preferences. Limitations and gaps in the evidence are highlighted to guide future research opportunities.


Subject(s)
Adenocarcinoma , Barrett Esophagus , Endoscopic Mucosal Resection , Esophageal Neoplasms , Esophagoscopy , Barrett Esophagus/surgery , Barrett Esophagus/pathology , Humans , Esophageal Neoplasms/surgery , Esophageal Neoplasms/pathology , Endoscopic Mucosal Resection/adverse effects , Esophagoscopy/standards , Esophagoscopy/adverse effects , Adenocarcinoma/surgery , Adenocarcinoma/pathology , Gastroenterology/standards , Evidence-Based Medicine/standards , Treatment Outcome , Clinical Decision-Making , Ablation Techniques/adverse effects , Ablation Techniques/standards
6.
BMC Med Educ ; 24(1): 529, 2024 May 13.
Article in English | MEDLINE | ID: mdl-38741179

ABSTRACT

BACKGROUND AND AIMS: Management of inflammatory bowel disease is constantly evolving, increasing the importance for gastroenterologists to keep up to date with guidelines. Traditional implementation strategies have had only small positive impacts on clinical practice. eHealth strategies such as the European Crohn's and Colitis Organisation e-guide may be beneficial for clinician decision making in keeping with guidelines. The aim of this study was to evaluate the feasibility and acceptability of the e-guide. METHODS: A mixed methods approach was used to evaluate feasibility and acceptability. Cognitive (think-aloud) interviews were conducted with Australian gastroenterologists while using the e-guide. Two clinical scenarios were developed to allow evaluation of various aspects of the e-guide. Content analysis was applied to the qualitative interview data and descriptive analysis to the quantitative and observational data. RESULTS: Seventeen participants completed the study. Data saturation were reached. The ECCO e-guide was largely feasible and acceptable, as demonstrated by most clinical questions answered correctly, 87% reaching the answer within 3 min, and most feeling it was useful, would be beneficial to their practice and would use it again. Issues raised included difficulties with website navigation, layout of the e-guide and difficulties with access (network firewalls, paid subscription required). CONCLUSIONS: The ECCO e-guide is largely acceptable and feasible for gastroenterologists to use. Aspects of the e-guide could be modified to improve user experience. This study highlights the importance of engaging end-users in the development and evaluation of clinician educational tools.


Subject(s)
Crohn Disease , Feasibility Studies , Gastroenterologists , Guideline Adherence , Humans , Australia , Female , Male , Adult , Middle Aged , Practice Guidelines as Topic , Europe , Attitude of Health Personnel , Gastroenterology
7.
Hepatology ; 79(6): 1241-1242, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38758103
10.
Am J Nurs ; 124(6): 37, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38780337

ABSTRACT

These nurses focus on the care of patients with gastrointestinal issues.


Subject(s)
Gastroenterology , Humans , Nurse's Role , Specialties, Nursing , Endoscopy, Gastrointestinal/nursing
11.
J Gastroenterol ; 59(6): 437-441, 2024 06.
Article in English | MEDLINE | ID: mdl-38703187

ABSTRACT

Fluoroscopy-guided gastrointestinal procedures, including gastrointestinal stenting, balloon-assisted endoscopy (BAE), endoscopic retrograde cholangiopancreatography (ERCP), and endoscopic ultrasound (EUS), are essential for diagnosis and treatment in gastroenterology. Such procedures involve radiation exposure that necessitates strict safety measures to protect patients, doctors, and medical staff. The April 2020 update to Japan's Ionizing Radiation Injury Prevention Regulations for occupational exposure reduced the lens exposure dose limit to approximately one-seventh of its previous level. This change highlights the need for improved safety protocols. Without adaptation, the sustainability of fluoroscopy-based endoscopic techniques could be at risk due to the potential to exceed these new limits. This review examines the current state of medical radiation exposure in the field of gastroenterology in Japan and discusses the findings of the REX-GI study.


Subject(s)
Gastroenterology , Occupational Exposure , Radiation Exposure , Radiation Protection , Humans , Japan , Gastroenterology/methods , Gastroenterology/standards , Occupational Exposure/prevention & control , Occupational Exposure/adverse effects , Radiation Protection/methods , Radiation Exposure/prevention & control , Radiation Exposure/adverse effects , Fluoroscopy/adverse effects , Fluoroscopy/methods , Radiation Injuries/prevention & control , Radiation Dosage
12.
World J Gastroenterol ; 30(18): 2397-2401, 2024 May 14.
Article in English | MEDLINE | ID: mdl-38764768

ABSTRACT

Endohepatology describes the emerging field where diagnostic and therapeutic endoscopic ultrasound (EUS) are used for the diagnosis and management of liver disease and its sequelae. In this editorial we comment on the article by Gadour et al. The spectrum of EUS-guided procedures includes liver parenchymal and lesional biopsy, abscess drainage, treatment of focal liver lesions, diagnosis of portal hypertension and management of gastric varices. The data suggest that the application of EUS to hepatology is technically feasible and safe, heralding the arrival at a new frontier for EUS. More data, specifically randomised trials comparing EUS to interventional radiology techniques, and continued partnership between endoscopy and hepatology are required to see this field establish itself outside expert tertiary centres.


Subject(s)
Endosonography , Liver Diseases , Humans , Endosonography/methods , Liver Diseases/diagnostic imaging , Liver Diseases/therapy , Ultrasonography, Interventional/methods , Gastroenterology/methods , Predictive Value of Tests , Diffusion of Innovation
13.
Eur J Gastroenterol Hepatol ; 36(6): 735-741, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38683191

ABSTRACT

BACKGROUND: Data on the management of Hepatitis B-Delta (HB-D) by hepatogastroenterologists (HGs) practicing in nonacademic hospitals or private practices are unknown in France. OBJECTIVE: We aimed to evaluate the knowledge and practices of HGs practicing in nonacademic settings regarding HB-D. METHODS: A Google form document was sent to those HGs from May to September 2021. RESULTS: A total of 130 HGs (mean age, 45 years) have participated in this survey. Among HBsAg-positive patients, Delta infection was sought in only 89% of cases. Liver fibrosis was assessed using FibroScan in 77% of the cases and by liver biopsy in 81% of the cases. A treatment was proposed for patients with >F2 liver fibrosis in 49% of the cases regardless of transaminase levels and for all the patients by 39% of HGs. Responding HGs proposed a treatment using pegylated interferon in 50% of cases, bulevirtide in 45% of cases and a combination of pegylated interferon and bulevirtide in 40.5% of cases. Among the criteria to evaluate the treatment efficacy, a decrease or a normalization of transaminases was retained by 89% of responding HGs, a reduction of liver fibrosis score for 70% of them, an undetectable delta RNA and HBsAg for 55% of them and a 2 log 10 decline in delta viremia for 62% of the cases. CONCLUSION: Hepatitis Delta screening was not systematically performed in HBsAg-positive patients despite the probable awareness and knowledge of the few responders who were able to prescribe treatments of hepatitis delta.


Subject(s)
Gastroenterologists , Hepatitis D , Hepatitis Delta Virus , Practice Patterns, Physicians' , Adult , Female , Humans , Male , Middle Aged , Antiviral Agents/therapeutic use , Biopsy , France , Gastroenterology , Health Knowledge, Attitudes, Practice , Hepatitis B Surface Antigens/blood , Hepatitis Delta Virus/isolation & purification , Hepatitis Delta Virus/genetics , Liver Cirrhosis/virology , Practice Patterns, Physicians'/statistics & numerical data , Hepatitis D/blood , Hepatitis D/diagnosis , Hepatitis D/drug therapy , Hepatitis D/epidemiology
15.
Gastroenterology ; 166(6): 1182-1189, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38639677

ABSTRACT

DESCRIPTION: Pain is a common symptom among patients with inflammatory bowel disease (IBD). Although pain typically occurs during episodes of inflammation, it is also commonly experienced when intestinal inflammation is quiescent. Many gastroenterologists are at a loss how to approach pain symptoms when they occur in the absence of gut inflammation. We provide guidance in this area as to the evaluation, diagnosis, and treatment of pain among patients with IBD. METHODS: This CPU was commissioned and approved by the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the CPUC and external peer review through standard procedures of Gastroenterology. This expert commentary incorporates important as well as recently published studies in this field, and it reflects the experiences of the authors. Formal ratings regarding the quality of evidence or strength of the presented considerations were not included because systematic reviews were not performed.


Subject(s)
Gastroenterology , Inflammatory Bowel Diseases , Pain Management , Humans , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/therapy , Inflammatory Bowel Diseases/diagnosis , Gastroenterology/standards , Pain Management/methods , Pain Management/standards , Pain Measurement , Societies, Medical/standards
16.
17.
Aliment Pharmacol Ther ; 59(10): 1170-1182, 2024 May.
Article in English | MEDLINE | ID: mdl-38557953

ABSTRACT

BACKGROUND: Telehealth is a growing model of care, greatly accelerated with the demands of the COVID-19 pandemic. Telecare is a synchronous audio-visual or audio-only format of health delivery. AIMS: To evaluate the existing literature on telecare within adult gastroenterology subspecialties to determine if outcomes are comparable to traditional in-person consultations and to highlight the Pokapu Network, a local initiative in the Lakes Region of New Zealand, amongst these international findings. METHODS: We completed an OVID MEDLINE search using the terms gastroenterology, endoscopy, digestive system, inflammatory bowel disease, functional, hepatology, liver, telemedicine, telehealth, videoconferencing, remote consultation, video clinic and telephone clinic. RESULTS: Patients showed positive attitudes towards telecare and, in several reports, would elect to have telecare consults in the future. Telecare reduces travel time and out-of-pocket costs for patients and the need for patients to take time off work. Generally, patients engaging with telecare show equivalent health outcomes to patients engaging with traditional models of care. Patients from ethnic minority groups or lower socio-economic backgrounds, or who are older, are less likely to complete a 'successful' telecare consult. CONCLUSION: Telecare is a useful model of care to allow gastroenterology centres to function within the context of COVID-19 isolation and beyond. It has significant benefits for patients who face geographical and financial barriers to accessing healthcare. Telecare models such as the Pokapu Network hold promise in reducing inequities for gastroenterology patients. Such models must be introduced with consideration of digital disparities that exist amongst patients to avoid worsening the digital divide.


Subject(s)
COVID-19 , Gastroenterology , Telemedicine , Humans , COVID-19/epidemiology , Telemedicine/methods , New Zealand , SARS-CoV-2 , Gastrointestinal Diseases/therapy
18.
BMJ Open Gastroenterol ; 11(1)2024 Apr 30.
Article in English | MEDLINE | ID: mdl-38688716

ABSTRACT

BACKGROUND: The updated Shape of Training curriculum has shortened the duration of specialty training. We present the potential role of out of programme clinical fellowships. METHOD: An electronic online survey was sent to all current fellows to understand their experiences, training opportunities and motivations.Data were collected on fellows' endoscopic experiences and publications using PubMed for all previous doctors who have completed the Sheffield Fellowship Programme. RESULTS: Since 2004, 39 doctors have completed the Sheffield Fellowship.Endoscopic experience: current fellows completed a median average of 350 (IQR 150-500) gastroscopies and 150 (IQR 106-251) colonoscopies per year. Fellows with special interests completed either 428 hepato-pancreato-biliary procedures or 70 endoscopic mucosal resections per year.Medline publications: Median average 9 publications(IQR 4-17). They have also received multiple national or international awards and 91% achieved a doctoral degree.The seven current fellows in the new Shape of Training era (57% male, 29% Caucasian, aged 31-40 years) report high levels of enjoyment due to their research projects, supervisory teams and social aspects. The most cited reasons for undertaking the fellowship were to develop a subspecialty interest, take time off the on-call rota and develop endoscopic skills. The most reported drawback was a reduced income.All current fellows feel that the fellowship has enhanced their clinical confidence and prepared them to become consultants. CONCLUSION: Out of programme clinical fellowships offer the opportunity to develop the required training competencies, subspecialty expertise and research skills in a supportive environment.


Subject(s)
Curriculum , Education, Medical, Graduate , Fellowships and Scholarships , Gastroenterology , Humans , Fellowships and Scholarships/statistics & numerical data , Male , Female , Adult , Gastroenterology/education , Education, Medical, Graduate/methods , Surveys and Questionnaires , Cohort Studies , Career Choice
19.
Ann Intern Med ; 177(5_Supplement): S27-S36, 2024 May.
Article in English | MEDLINE | ID: mdl-38621241

ABSTRACT

This article summarizes clinically important gastroenterology developments from 2023 for internal medicine specialists. In colorectal cancer screening, a new RNA fecal screening test is on the horizon, as well as a new analysis on the benefits of using artificial intelligence in screening colonoscopy to detect more polyps. There is new evidence for management of gastrointestinal bleeding, a new drug for treatment of recurrent small-intestinal angiodysplasia, and a new endoscopic treatment method in patients with gastrointestinal tumor bleeding. The authors feature a randomized trial about amitriptyline as treatment for patients with irritable bowel syndrome by primary care providers and bring you news about new biologic agents for inflammatory bowel disease and eosinophilic esophagitis. Finally, they review 2 important articles on new terminology and management of metabolic dysfunction-associated fatty liver disease.


Subject(s)
Early Detection of Cancer , Humans , Gastrointestinal Hemorrhage/diagnosis , Gastroenterology , Colorectal Neoplasms/diagnosis , Colonoscopy , Gastrointestinal Diseases/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...